Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection
暂无分享,去创建一个
V. Calvez | G. Carcelain | R. Tubiana | A. Samri | C. Delaugerre | H. Agut | C. Katlama | B. Autran
[1] B. Autran,et al. Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. , 1992, The Journal of clinical investigation.
[2] C. Katlama,et al. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. , 1992, Journal of acquired immune deficiency syndromes.
[3] H. Nitschko,et al. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. , 1995, AIDS research and human retroviruses.
[4] J Leibowitch,et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.
[5] E. Rosenberg,et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.
[6] B. Hoen,et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. , 1998, The Journal of infectious diseases.
[7] M A Nowak,et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.
[8] Rob J. De Boer,et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.
[9] V. Calvez,et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease , 1998, The Lancet.
[10] Felipe García,et al. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease , 1998, The Lancet.
[11] J. Mellors,et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. , 1999, The Journal of infectious diseases.
[12] V. Calvez,et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.
[13] R. Steinman,et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. , 1999, AIDS.
[14] N. Foudraine,et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. , 1999, The Journal of infectious diseases.
[15] C. Pitcher,et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.
[16] A. Trkola,et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.
[17] M. Nowak,et al. Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy , 1999, Journal of Virology.
[18] J. Lisziewicz,et al. Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.
[19] T. Merigan,et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). , 1999, Journal of immunology.
[20] R. Paredes,et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.
[21] D. Nixon,et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. , 2000, The Journal of infectious diseases.
[22] P. Easterbrook,et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.